Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed

ALNYLAM PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$1.53 revenue$1,655,077,000

Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.
GAAP net loss $111.6M ($0.87 loss per share) vs. prior-year net income $147.8M ($1.18); Non-GAAP loss $64.2M ($0.50).
Submitted sNDA in U.S. and Type II Variation in EU for vutrisiran in ATTR-CM using Priority Review Voucher; potential U.S. launch early 2025.
Positive Phase 1 mivelsiran data in Alzheimer's: >90% sAPPβ lowering after second dose; no new safety signals. Ph2 planned year-end.
Suspended ALN-KHK development for type 2 diabetes; appointed Robert Hesslein as Chief Legal Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.